Marcela V. Maus, M.d.,ph.d.

This early-phase trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful B cells. It is for 12 adults with severe ANCA-associated vasculitis that has not responded to standard therapies. The main goals are to c…

This early-phase study tests a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a fast-growing brain cancer. The treatment uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor side effect…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This study tests whether the drug emapalumab can prevent severe inflammatory side effects (cytokine release syndrome) caused by CAR-T cell therapy. About 28 adults with relapsed or refractory large B-cell lymphoma will receive emapalumab alongside standard CAR-T treatment. The go…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or not responded to standard therapies. About 18 adults will receive the therapy along with two chemotherapy drugs to prepare the body. The main goal is to c…

This study follows 45 adults who previously received CAR T cells in two earlier trials. Researchers will track participants for long-term side effects, survival, and whether the cancer stays away. The goal is to better understand the lasting safety and effectiveness of this treat…